Jump to content

Flunisolide

From Wikipedia, the free encyclopedia

This is an old revision of this page, as edited by DePiep (talk | contribs) at 13:36, 2 April 2016 (Remove redundant parameters InChI, InChIKey (using StdInChI, StdInChIKey). See Talk (via AWB script)). The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.

Flunisolide
Clinical data
Trade namesAerobid
Other names6α-Fluoro-11β,16α,17,21-tetrahydroxypregna-1,4-diene-3,20-dione acetone cyclic 16,17-acetal
AHFS/Drugs.comMonograph
MedlinePlusa681048
Routes of
administration		Inhaled
ATC code
Pharmacokinetic data
Protein binding40% after oral inhalation
Elimination half-life1.8 hours
Identifiers
  • (1S,2S,4R,8S,9S,11S,12S,13R,19S)-19-fluoro-11-hydroxy-8-(2-hydroxyacetyl)-6,6,9,13-tetramethyl-5,7-dioxapentacyclo[10.8.0.02,9.04,8.013,18]icosa-14,17-dien-16-one
CAS Number
PubChem CID
IUPHAR/BPS
DrugBank
ChemSpider
UNII
KEGG
ChEBI
ChEMBL
CompTox Dashboard (EPA)
ECHA InfoCard100.020.177 Edit this at Wikidata
Chemical and physical data
FormulaC24H31FO6
Molar mass434.498 g/mol g·mol−1
3D model (JSmol)
  • O=C\1\C=C/[C@]2(/C(=C/1)[C@@H](F)C[C@H]3[C@H]4[C@](C[C@H](O)[C@H]23)([C@@]5(OC(O[C@@H]5C4)(C)C)C(=O)CO)C)C
  • InChI=1S/C24H31FO6/c1-21(2)30-19-9-14-13-8-16(25)15-7-12(27)5-6-22(15,3)20(13)17(28)10-23(14,4)24(19,31-21)18(29)11-26/h5-7,13-14,16-17,19-20,26,28H,8-11H2,1-4H3/t13-,14-,16-,17-,19+,20+,22-,23-,24+/m0/s1 checkY
  • Key:XSFJVAJPIHIPKU-XWCQMRHXSA-N checkY
 ☒NcheckY (what is this?)  (verify)

Flunisolide (marketed as AeroBid, Nasalide, Nasarel) is a corticosteroid often prescribed as treatment for allergic rhinitis.[1] Intranasal corticosteroids are the most effective medication for controlling symptoms. [2] In the United Kingdom it was formerly marketed as Syntaris, but this was recently discontinued by the manufacturers.[3]

The principal mechanism of action of flunisolide is to activate glucocorticoid receptors, meaning it has an anti-inflammatory action. The effects of topical corticosteroids is not immediate and requires regular use and at least a few days to start experiencing noticeable symptom relief. As-needed use has been shown to be not as effective as regular recommended use. [4] Flunisolide should not be used in the presence of nasal infection. It should not be continued if there is no relief of symptoms after regular use over two to three weeks. [5]

Side effects

Temporary nose and throat dryness, irritation, bleeding or unpleasant taste or smell may occur.[6] Nasal septum perforation is rarely reported. [7] Rare, but localized infections of the nose and pharynx with Candida albicans have been reported and long-term use may raise the chance of cataracts or glaucoma.[8]

Flunisolide nasal spray is absorbed into the circulatory system (blood).[9] Corticosteroid nasal sprays may affect the hypothalamic-pituitary-adrenal axis function in humans.[10] After the desired clinical effect is obtained, the maintenance dose should be reduced to the smallest amount necessary to control symptoms, which can be as low as 1 spray in each nostril a day. Utilizing the minimum effective dose will reduce possibility of side effects.[11]Recommended amounts of intranasal corticosteroids are generally not associated with systemic side effects.

Corticosteroids inhibit wound healing. Therefore, use of corticosteroid nasal sprays in patients who have experienced recent nasal septal ulcers, recurrent epistaxis, nasal surgery or trauma, a nasal corticosteroid should be used with caution until healing has occurred.[12] In pregnancy, recommended doses of intranasal corticosteroids are safe and effective.[13]

References

  1. ^ See http://www.drugbank.ca/drugs/DB00180
  2. ^ "The diagnosis and management of rhinitis: an updated practice parameter". Allergy and Clinical Immunology. 122: S1-84. Aug 2008. doi:10.1016/j.jaci.2008.06.003. PMID 18662584.
  3. ^ See http://www.pharphar.com/v/Syntaris
  4. ^ "The diagnosis and management of rhinitis: an updated practice parameter". Allergy and Clinical Immunology. 122: S1-84. Aug 2008. doi:10.1016/j.jaci.2008.06.003. PMID 18662584.
  5. ^ http://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=8ba9cc1c-55e5-40ed-9efe-f7abb73976ea
  6. ^ http://www.medicinenet.com/flunisolide-nasal/page2.htm
  7. ^ "The diagnosis and management of rhinitis: an updated practice parameter". Allergy and Clinical Immunology. 122: S1-84. Aug 2008. doi:10.1016/j.jaci.2008.06.003. PMID 18662584.
  8. ^ http://www-uptodate-com.ucsf.idm.oclc.org/contents/flunisolide-nasal-patient-drug-information?source=search_result&search=flunisolide&selectedTitle=3~14
  9. ^ http://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=8ba9cc1c-55e5-40ed-9efe-f7abb73976ea
  10. ^ http://www.rxlist.com/nasalide-drug/clinical-pharmacology.htm
  11. ^ http://www.rxlist.com/nasalide-drug/clinical-pharmacology.htm
  12. ^ http://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=8ba9cc1c-55e5-40ed-9efe-f7abb73976ea
  13. ^ "The diagnosis and management of rhinitis: an updated practice parameter". Allergy and Clinical Immunology. 122: S1-84. Aug 2008. doi:10.1016/j.jaci.2008.06.003. PMID 18662584.


Retrieved from "https://en.wikipedia.org/w/index.php?title=Flunisolide&oldid=713183541"